European Journal of Haematology

Papers
(The H4-Index of European Journal of Haematology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Issue Information77
47
45
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect37
Post‐transplant maintenance therapy in patients with FLT3‐mutated acute myeloid leukemia: Real‐world treatment patterns and outcomes34
Enhancing thalassemia gene carrier identification in non‐anemic populations using artificial intelligence erythrocyte morphology analysis and machine learning33
Issue Information29
Issue Information27
The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review25
Long‐term effectiveness of eculizumab: Data from the International PNH Registry25
Effects of tertiary palliative care on the pattern of end‐of‐life care in patients with hematologic malignancies in Korea23
Plasma microbial cell‐free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia22
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma22
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes22
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes21
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)‐T cell therapy in patients with hematological malignancy19
Flow cytometry for comprehensive assessment of platelet functional activity in response to ADP stimulation19
Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma18
0.073166847229004